Akers Biosciences Share Discussion Threads

[mcmather] 21/11/2014 13:16

Unrelated of course to anything on here.....

World's Biggest Liar title won by?

[mcmather] 21/11/2014 11:44

Count (Ray)von Count

$1, ha ha ha
$2, ha ha ha
.........
$330,000 ha ha ha

[algernon2] 21/11/2014 09:46

"Akers Biosciences comes to you today with the word "Down" and the number "2""
==============
Just like Sesame Street as I recall the opening.

[norbus] 19/11/2014 12:09

mcm

You know without the Brit fundmanager who invested, there but for the grace of G-d,,,,, NAZDAQ would never have been realised; Why does your group not write to the man with >6% ? and ask him if he is a happy bunny? TAN has another job; you could write and ask him how he sees things going, then switch into ITM.

[mcmather] 19/11/2014 11:47

Which bit?

[deanroberthunt] 19/11/2014 11:40

it's not difficult.

[deanroberthunt] 19/11/2014 10:44

amazing that AIM Directors salaries are better than some FTSE100 stocks....even though they are loss making....aha therein lies the problem.

[deanroberthunt] 19/11/2014 10:43

keep up the good work, right up to the next placing.

[mcmather] 19/11/2014 10:27

Re "Akers Biosciences has significant Third World opportunity" from the company's twitter page. What about the US? What about the PIFA range in the US? In EU?

What about Tri-Cholesterol? In the US? In the EU?

What about Chube?

What about Metron?

What about VIVO?

Worryingly, that comment strikes me that Akers' place in the market may be in the "Third World" and not at the forefront of matters in the US, EU, China / Japan / UAE / Aus / etc??

[mcmather] 19/11/2014 10:19

Aye but both finncap and redchip are paid advisors. Redchip have toed this line since coming on board at the IPO stage.

There is, of course, some use in the research notes. However, the actual performance of the company as 2014 progresses is deteriorating with expenses and losses massively increasing.

Historically, if you look at the RNS's issued by the company, the standard theme was it is coming together, next 3/6/12 months, etc. Have a look at post 2608 and then review ANY rns after 7 April 2008 to about 2013.

Dr Raymond Akers has said all year long - except for the past 6 weeks or so - that the company would be cash neutral by 2014 y/e (see above re next time / quarter / year / etc). Simply based on what he has said for the most of 2014 pertaining to the performance of Akers Biosciences, Dr Raymond Akers does not appear to be a person that one should place too much (any?) trust on.

Since I have been reviewing matters here (4 years or so), Dr Raymond Akers has been on a package of around $300k per year. AKR came to AIM in May 2002. The current funds will mean that he will likely have banked approaching $5m by the time that the company purportedly becomes genuinely profitable. A genuine question but is he serving our benefit as shareholders or are we simply serving his benefit?

[deanroberthunt] 19/11/2014 09:47

Yeah and QPP was worth £3-4bn according to it's now ousted BODs......lol

[rivaldo] 19/11/2014 09:26

New Redchip research report just out - note the $10.8m cash compared to the £10.65m m/cap:



Conclusion:

"Target price of $11.40. We are applying a 5.0x P/S multiple to our projected FY15 revenue per share of $2.25. Our target price offers significant upside from the current price of $3.13. We believe the current entry point is very attractive, especially considering that AKER is trading just below book value (0.99x), has no debt, is generating revenue both domestically and internationally and has many pending product launches on the horizon."

[mcmather] 18/11/2014 16:54

Possibly but the PIFA/PF4 device was the main revenue maker during TAN's time here and the figures were as they are now; ie embarrassing.

Of course, the difference now is that more chums are on board - why is Knox a party in his own right on the recent JV in China?? - and so Raymond's year long predictions of being cash neutral by year end are in the same place as his credibility and reputation.

[norbus] 18/11/2014 15:32

Salaries and benefits I presume dear chap; maybe need to ask Thomas why he left having engineered the NASDAQ quote. Some'at wrong with Raymond?

[deanroberthunt] 18/11/2014 15:11

Keep up the good work boys as the bod fill their pockets at the expense of shareholders......see you at 100p

[rivaldo] 18/11/2014 12:26

Further brief comments from Finncap FYI:

"Akers' rapid diagnostic tests surpass most other current diagnostic tests with their portability, speed, ease-of-use, low cost and accuracy."

"We forecast revenues to rise at a compound rate of 53% between this year and 2017"

Sales are forecast to rise to $7.2m in 2015 from $4.6m this year, and the $10.2m cash should see AKR through to profitability.

[mcmather] 18/11/2014 09:06

It's something but even if achieved that will still be well below the nasdaq IPO of less than 10 months ago; I would not be happy with the performances of either Dr Raymond Akers or Edwin C Hendrick if I had invested here at the IPO.

Since the IPO and for most of 2014 Dr Raymond Akers has been predicting that the company which bears his name will be cash neutral by y/e 2014.

Q1 2014 - "Net loss of $595,600 mainly due to costs associated with NASDAQ IPO".

H1 2014 - "a net loss of $1,090,595. Three factors contributed to the increased loss: maintaining dual listings of our stock has significantly increased costs associated with compliance with regulatory requirements, the expansion of sales and marketing efforts and stock option based compensation for our directors, officers and key employees; just wrong on every level.

Q3 2014 - "Net loss of $1,055,913 for the third quarter as a result of hiring additional personnel, capital market commitments and marketing activities".

Sadly, what Dr Raymond Akers does and say, in my opinion, needs to be treated very, very carefully.

[rivaldo] 18/11/2014 08:38

Nice - Finncap have today begun coverage of AKR with an initial 310p price target:

"Akers Biosciences* - Testing, testing…(235.0p)

AKR – CORP– TP: 310.0p.– Market Cap: £11.5m

Akers Biosciences develops, manufactures and supplies rapid, point-of-care screening and testing products in a wide variety of healthcare specialties. In 2014, the company raised $15m in gross proceeds which should be sufficient to fund operations through to cash flow breakeven status, which we anticipate to occur in mid-to late 2016. We anticipate that revenue will grow between 2014 and 2017 at a CAGR of 53%, and we initiate our coverage with a 310p target price, which is based both on a peer group comparison, and a discounted cash flow model."

[mcmather] 13/11/2014 23:24

13 November 2014 - "Domestic sales of our current flagship PIFA Heparin/PF4 Rapid Assay products are currently driving sales while we establish the foundations for an international sales push," said Raymond F. Akers, Jr. PhD, Co-founder and Executive Chairman of the Board.

7 April 2008 - ramp up sales of Heparin/Platelet Factor-4 antibodies test into a small hospital customer base which, with very satisfactory product acceptance by clinicians, is expected to contribute significantly to future growth;

The Company's rapid HPF4 test is sold into the US clinical laboratory market through Cardinal Health and Corgenix Medical Group under the Company's brand
"PIFA Heparin/PF-4 Rapid Assay." This is the first rapid test for HPF4 antibodies, and the product is protected by two of the Company's patents, with
additional patents pending. The market response clearly indicates a significant
clinical need for the product, and several studies have been presented at
scientific meetings indicating that the Company's test may be more accurate than
any competitor on the market.

In 2007 Cardinal Health signed a new distribution contract with the Company that
guarantees that the product will remain in Cardinal's highest focus of products
at least through 2008, and that the Company will be in the highest tier of
supplier relationships. We are exploring additional ways to rapidly increase market penetration of this product.

Conclusion? Either way Dr Raymond Akers has been receiving a salary of around $300,000 for each of the 6 1/2 years time span between those two statements.

[mcmather] 13/11/2014 13:00

Revenue in Q4 2013 was $571,473.

Q3 2014 with all the investment, recruitment, restructuring, expenses, etc, etc, totaled $453,313.

How does the management justify that?

Sorry, but that is a disgraceful effort and performance Dr Raymond Akers. Shameful.

[mcmather] 13/11/2014 12:14

Dr Raymond Akers and Edwin C. Hendrick should be thoroughly ashamed by these figures; this relates to annual revenue for the year of under $2m.

"Revenue for the third quarter totaled $453,313 (Q3 2013: $344,709), a 32% increase from the same period in 2013, primarily driven by sales of PIFA Heparin/PF4 Rapid Assay products in the US"

Net loss for the third quarter attributable to shareholders of $1,124,320 (Q3 2013: $544,370) as a result of hiring additional personnel, capital market commitments and marketing activities.

[mcmather] 13/11/2014 12:12

Dr Raymond Akers and Edwin C. Hendrick should be thoroughly ashamed by these figures; this relates to annual revenue for the year of $1.8m.

"Revenue for the third quarter totaled $453,313 (Q3 2013: $344,709), a 32% increase from the same period in 2013, primarily driven by sales of PIFA Heparin/PF4 Rapid Assay products in the US "